Kaida Wu

1.4k total citations
37 papers, 922 citations indexed

About

Kaida Wu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kaida Wu has authored 37 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Kaida Wu's work include Multiple Myeloma Research and Treatments (15 papers), Telomeres, Telomerase, and Senescence (8 papers) and Acute Myeloid Leukemia Research (5 papers). Kaida Wu is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Telomeres, Telomerase, and Senescence (8 papers) and Acute Myeloid Leukemia Research (5 papers). Kaida Wu collaborates with scholars based in United States, France and Spain. Kaida Wu's co-authors include Malcolm A.S. Moore, Selina Chen‐Kiang, Karen Bang, Kristian Thestrup‐Pedersen, Marianne Lund, Rachel A. Gottschalk, Scott Ely, Rubén Niesvizky, Maurizio Di Liberto and Linda B. Baughn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Kaida Wu

36 papers receiving 911 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kaida Wu United States	17	527	401	295	191	135	37	922
Silvana Di Giandomenico United States	10	537 1.0×	224 0.6×	263 0.9×	58 0.3×	87 0.6×	16	865
Matilda Rehn Sweden	12	382 0.7×	285 0.7×	179 0.6×	61 0.3×	112 0.8×	24	862
W Zhang United States	13	550 1.0×	144 0.4×	437 1.5×	58 0.3×	90 0.7×	19	1.0k
Shuhei Koide Japan	17	649 1.2×	276 0.7×	171 0.6×	34 0.2×	93 0.7×	48	932
Kimberly Lezon-Geyda United States	16	473 0.9×	125 0.3×	162 0.5×	209 1.1×	112 0.8×	34	860
Ken Maes Belgium	23	1.0k 1.9×	643 1.6×	396 1.3×	36 0.2×	131 1.0×	50	1.5k
Pamela N. Pharr United States	13	335 0.6×	259 0.6×	161 0.5×	129 0.7×	120 0.9×	22	739
Carolina Vicente‐Dueñas Spain	18	728 1.4×	169 0.4×	495 1.7×	37 0.2×	110 0.8×	41	1.2k
Irina Sadovnik Austria	18	452 0.9×	551 1.4×	409 1.4×	39 0.2×	273 2.0×	38	1.2k
Anna Dolnik Germany	15	564 1.1×	333 0.8×	151 0.5×	35 0.2×	190 1.4×	39	900

Countries citing papers authored by Kaida Wu

Since Specialization

Citations

This map shows the geographic impact of Kaida Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaida Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaida Wu more than expected).

Fields of papers citing papers by Kaida Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaida Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaida Wu. The network helps show where Kaida Wu may publish in the future.

Co-authorship network of co-authors of Kaida Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Kaida Wu. A scholar is included among the top collaborators of Kaida Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaida Wu. Kaida Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abdul‐Hay, Maher, Onyee Chan, Namrata S. Chandhok, et al.. (2025). Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS). Blood. 146(Supplement 1). 768–768.

Heitmann, Jonas S., Juliane S. Walz, Helmut R. Salih, et al.. (2024). A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. Blood. 144(Supplement 1). 2883.1–2883.1. 1 indexed citations

Sauer, Karsten, Kavya Rakhra, Kaida Wu, et al.. (2024). Intratumoral injection and retention hold promise to improve cytokine therapies for cancer. Frontiers in Oncology. 14. 1456658–1456658. 1 indexed citations

Façon, Thierry, Sagar Lonial, Brendan M. Weiss, et al.. (2017). Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001. Blood. 130. 1824–1824. 15 indexed citations

Lonial, Sagar, Jesús F. San Miguel, Joaquín Martínez‐López, et al.. (2017). Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study. Blood. 130. 1869–1869. 9 indexed citations

Chari, Ajai, Saad Z. Usmani, Amrita Krishnan, et al.. (2017). Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study. Blood. 130. 3110–3110. 23 indexed citations

Pozdnyakova, Olga, Kaida Wu, Abhay Patki, et al.. (2014). High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Modern Pathology. 27(11). 1447–1454. 17 indexed citations

Jamieson, Catriona, Robert P. Hasserjian, Jason Gotlib, et al.. (2013). Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. Blood. 122(21). 2823–2823. 6 indexed citations

Gerecitano, John F., Joe Stephenson, Nancy Lewis, et al.. (2012). A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Investigational New Drugs. 31(2). 355–362. 30 indexed citations

10.

Thestrup‐Pedersen, Kristian, Ranjit S. Parhar, Kaida Wu, et al.. (2007). Skin-homing CD8+ T lymphocytes Show Preferential Growth in vitro and Suppress CD4+ T-cell Proliferation in Patients with Early Stages of Cutaneous T-cell Lymphoma. Acta Dermato Venereologica. 87(2). 118–126. 4 indexed citations

11.

Baughn, Linda B., Maurizio Di Liberto, Kaida Wu, et al.. (2006). A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6. Cancer Research. 66(15). 7661–7667. 172 indexed citations

12.

Wu, Kaida, et al.. (2006). Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunology Immunotherapy. 56(3). 343–357. 45 indexed citations

13.

Padilla‐Nash, Hesed, et al.. (2006). Spectral karyotyping demonstrates genetically unstable skin‐homing T lymphocytes in cutaneous T‐cell lymphoma. Experimental Dermatology. 16(2). 98–103. 10 indexed citations

14.

Lanza, Robert, Jae-Hung Shieh, Peter J. Wettstein, et al.. (2005). Long-Term Bovine Hematopoietic Engraftment with Clone-Derived Stem Cells. Cloning and Stem Cells. 7(2). 95–106. 6 indexed citations

15.

Lanza, Robert, Peter J. Wettstein, Raymond W. Sweeney, et al.. (2005). Long-Term Bovine Hematopoietic Engraftment with Clone-Derived Stem Cells. Cloning and Stem Cells. 0(0). 3240688017–3240688017. 1 indexed citations

16.

Wu, Kaida & Malcolm A.S. Moore. (2005). Determination of Telomerase Activity and Telomere Length. Humana Press eBooks. 113. 207–224. 3 indexed citations

17.

Chen‐Kiang, Selina, Scott Ely, Maurizio Di Liberto, et al.. (2005). Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.. Blood. 106(11). 1564–1564. 1 indexed citations

18.

Wu, Kaida, et al.. (2001). Expression and Function of CD43 and CDw60 on T Cells from Patients with Atopic Dermatitis. Acta Dermato Venereologica. 81(4). 263–267. 3 indexed citations

19.

Wu, Kaida, et al.. (2000). Telomerase Activity Is Increased and Telomere Length Shortened in T Cells from Blood of Patients with Atopic Dermatitis and Psoriasis. The Journal of Immunology. 165(8). 4742–4747. 72 indexed citations

20.

Wu, Kaida, et al.. (1999). Telomerase activity is spontaneously increased in lymphocytes from patients with atopic dermatitis and correlates with cellular proliferation. Journal of Dermatological Science. 22(1). 24–30. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact